Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 The A-R-CHOP regimen*

From: Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma

Drug Dose Mode  
Bevacizumab† 15 mg/kg i.v. D1
Rituximab‡ 375 mg/m2 i.v. D1
Cyclophosphamide 750 mg/m2 i.v. D1
Doxorubicin 50 mg/m2 i.v. D1
Vincristine 1.4 mg/m2 (≤2 mg) i.v. D1
Prednisone 100 mg/d p.o. D1-5
  1. *1 cycle per 21 days †bevacizumab was given prior to rituximab, the infusion time of bevacizumab is one hour. ‡the infusion time of rituximab is five hours.